{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:07:55Z","timestamp":1789132075100,"version":"build-2803163510"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neuroscience.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:47:29Z","timestamp":1785858449000},"page":"32-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An updated patent review of mGlu5 negative allosteric modulators (2018 \u2212 present)"],"prefix":"10.1016","volume":"614","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7947-5337","authenticated-orcid":false,"given":"Manka","family":"Marycleopha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2026.08.002_b0005","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2147\/NDT.S379395","article-title":"Differences in mGluR5 availability depending on the level of social avoidance in drug-na\u00efve young patients with major depressive disorder","volume":"18","author":"Kim","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.apha.2015.11.001","article-title":"Modulation of chronic pain by metabotropic glutamate receptors","volume":"75","author":"Chiechio","year":"2016","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0015","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/13543776.2017.1280466","article-title":"mGlu5 negative allosteric modulators: a patent review (2013\u20132016)","volume":"27","author":"Emmitte","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/biom15040552","article-title":"Activation of endoplasmic reticulum-localized metabotropic glutamate receptor 5 (mGlu5) triggers calcium release distinct from cell surface counterparts in striatal neurons","volume":"15","author":"Jong","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.00038","article-title":"Exploring the activation mechanism of the mGlu5 transmembrane domain","volume":"7","author":"Lans","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94967-y","article-title":"In vivo imaging of mGlu5 receptor expression in humans with Fragile X syndrome towards development of a potential biomarker","volume":"11","author":"Mody","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/cells12071004","article-title":"Effect of the metabotropic glutamate receptor type 5 negative allosteric modulator dipraglurant on motor and non-motor symptoms of Parkinson\u2019s disease","volume":"12","author":"Epping-Jordan","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0040","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1021\/acsptsci.4c00213","article-title":"Pharmacology, signaling and therapeutic potential of metabotropic glutamate receptor 5 negative allosteric modulators","volume":"7","author":"Kos","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134427","article-title":"Levodopa-Induced dyskinesias in Parkinson\u2019s disease: an overview on pathophysiology, clinical manifestations, therapy management strategies and future directions","volume":"12","author":"di Biase","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0050","first-page":"13","article-title":"Targeting the Type 5 metabotropic glutamate receptor: a potential therapeutic strategy for neurodegenerative diseases?","author":"Budgett","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0055","doi-asserted-by":"crossref","DOI":"10.1177\/2470547019837712","article-title":"Targeting of metabotropic glutamate receptors for the development of novel antidepressants","volume":"3","author":"Chaki","year":"2019","journal-title":"Chronic Stress"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi4505","article-title":"Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial","volume":"17","author":"Gomez-Mancilla","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0070","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","article-title":"A phase 2A trial of the novel mglur5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson\u2019s disease","volume":"31","author":"Tison","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0075","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/13543776.2013.760544","article-title":"MGlu5 negative allosteric modulators: a patent review (2010-2012)","volume":"23","author":"Emmitte","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0080","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1021\/acschembio.2c00234","article-title":"Structure-based discovery of negative allosteric modulators of the metabotropic glutamate receptor 5","volume":"17","author":"Kampen","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/jpet.120.000371","article-title":"Understanding exposure-receptor occupancy relationships for metabotropic glutamate receptor 5 negative allosteric modulators across a range of preclinical and clinical studies","volume":"377","author":"Bennett","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0090","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1021\/acsmedchemlett.4c00481","article-title":"Discovery of 4-(5-membered)heteroarylether-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5","volume":"15","author":"Childress","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/toxics13070519","article-title":"Glutamate-mediated neural alterations in lead exposure: mechanisms pathways, and phenotypes","volume":"13","author":"Tamagno","year":"2025","journal-title":"Toxics"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0100","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-024-01385-z","article-title":"Metabotropic glutamate receptor 5 (mGluR5) is associated with neurodegeneration and amyloid deposition in Alzheimer\u2019s disease: a [18F]PSS232 PET\/MRI study","volume":"16","author":"Wang","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0105","unstructured":"Gazzette (2007) European Patent Specification."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.celrep.2017.06.023","article-title":"Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimer\u2019s mouse phenotypes","volume":"20","author":"Haas","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.119.119032","article-title":"Detailed in vitro pharmacological characterization of clinically tested negative allosteric modulators of the metabotropic glutamate receptor 5","volume":"98","author":"Arsova","year":"2020","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0120","doi-asserted-by":"crossref","unstructured":"Lea PM, Faden AI (2006) Metabotropic Glutamate Receptor Subtype 5 Antagonists MPEP and MTEP.","DOI":"10.1111\/j.1527-3458.2006.00149.x"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0125","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/npp.2017.177","article-title":"Effect of the mGluR5-NAM basimglurant on behavior in adolescents and adults with fragile X syndrome in a randomized, double-blind, placebo-controlled trial: fragxis phase 2 results","volume":"43","author":"Youssef","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0130","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1021\/acschemneuro.2c00674","article-title":"Emerging therapeutic strategies for fragile X syndrome: Q&A","volume":"13","author":"Alusi","year":"2022","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0135","first-page":"9","article-title":"Fragile X targeted pharmacotherapy: Lessons learned and future directions","author":"Erickson","year":"2017","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-025-01138-1","article-title":"Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson\u2019s disease","volume":"11","author":"Alborghetti","year":"2025","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1124\/jpet.114.222463","article-title":"Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression","volume":"353","author":"Lindemann","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0150","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1016\/j.bmc.2014.09.033","article-title":"AFQ056\/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization","volume":"22","author":"Vranesic","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0155","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175036","article-title":"Challenges in developing therapies in fragile X syndrome: how the FXLEARN trial can guide research","volume":"134","author":"Neul","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0160","article-title":"Advances in non-dopaminergic treatments for Parkinson\u2019s disease","author":"Stayte","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0165","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.chembiol.2017.06.003","article-title":"Mechanisms of skin toxicity associated with metabotropic glutamate receptor 5 negative allosteric modulators","volume":"24","author":"Shah","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.beem.2013.05.010","article-title":"Calcium-sensing receptor (CaSR): Pharmacological properties and signaling pathways","volume":"27","author":"Conigrave","year":"2013","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0175","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1021\/acs.jmedchem.5b00892","article-title":"Fragment and structure-based drug discovery for a class C GPCR: discovery of the mGlu5 negative allosteric modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)","volume":"58","author":"Christopher","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.700822","article-title":"Partial mGlu5 negative allosteric modulator M-5MPEP demonstrates antidepressant-like effects on sleep without affecting cognition or quantitative EEG","volume":"15","author":"Holter","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109648","article-title":"Agonists and allosteric modulators promote signaling from different metabotropic glutamate receptor 5 conformations","volume":"36","author":"Nasrallah","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0190","doi-asserted-by":"crossref","unstructured":"Razzak MA, Tran K, McCague R, et al (2024) Pharmacological characterisation of allosteric modulators at human mGlu 5.","DOI":"10.1101\/2024.12.05.627101"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0195","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/npp.2014.245","article-title":"Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles","volume":"40","author":"Rook","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2015.00215","article-title":"Therapeutic potential of mGluR5 targeting in Alzheimer\u2019s disease","volume":"9","author":"Kumar","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115867","article-title":"The density of group i mglu5 receptors is reduced along the neuronal surface of hippocampal cells in a mouse model of Alzheimer \u2019s disease","volume":"22","author":"Mart\u00edn-Belmonte","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0210","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1021\/acsmedchemlett.5c00119","article-title":"Discovery of thieno[3,2-b]pyridine-5-carboxamide and 2,3-difluorobenzamide negative allosteric modulators of metabotropic glutamate receptor subtype 5","volume":"16","author":"Crocker","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29235724","article-title":"Insights into the metabolism, disposition, and quantitative profile of mGlu5 NAM AE90015 with metabolite identification and a novel integration method","volume":"29","author":"Zou","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0220","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/molpharm.120.000185","article-title":"Positive allosteric modulators of metabotropic glutamate receptor 5 as tool compounds to study signaling bias","volume":"99","author":"Arsova","year":"2021","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0225","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1021\/acs.jmedchem.7b00410","article-title":"Discovery of N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5 selected for clinical evaluation","volume":"60","author":"Felts","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0230","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/jnc.14844","article-title":"Metabotropic glutamate receptor 5 (mGlu5)-positive allosteric modulators differentially induce or potentiate desensitization of mGlu5 signaling in recombinant cells and neurons","volume":"151","author":"Hellyer","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0240","unstructured":"Dalton JAR, Lans I, Rovira X, et al (2016) Send Orders for Reprints to reprints@benthamscience.ae Shining Light on an mGlu5 Photoswitchable NAM: A Theoretical Perspective."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0245","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bmcl.2018.11.017","article-title":"Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5","volume":"29","author":"Felts","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0250","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejps.2017.07.031","article-title":"A phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers","volume":"109","author":"Haass-Koffler","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0255","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235639","article-title":"Small antibodies with big applications: nanobody-based cancer diagnostics and therapeutics","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0265","doi-asserted-by":"crossref","DOI":"10.3390\/biom16020324","article-title":"Glutamate metabotropic receptors-linked postsynaptic density proteins: an emergent hub for antipsychotics\u2019 regulation of synaptic plasticity and metaplasticity","volume":"16","author":"Barone","year":"2026","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0270","series-title":"International Review of Neurobiology","first-page":"93","article-title":"Metabotropic glutamate receptor function and regulation of sleep-wake cycles","author":"Holter","year":"2023"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0275","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci9050096","article-title":"Molecular biomarkers in fragile x syndrome","volume":"9","author":"Zafarullah","year":"2019","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acs.jmedchem.6b01453","article-title":"recent advances in structure-based drug design targeting class A G protein-coupled receptors utilizing crystal structures and computational simulations","volume":"61","author":"Lee","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0285","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature13396","article-title":"Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain","volume":"511","author":"Dor\u00e9","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0290","unstructured":"NIH (2022) TMP-301, A Negative Allosteric Modulator of type 5 metabotropic glutamate receptors (mGluR5), for Treatment of Cocaine Use Disorder."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0295","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.2174\/0109298673305662240702071354","article-title":"Hybrid\/chimera drugs - Part 1 - drug hybrids affecting diseases of the central nervous system","volume":"32","author":"Nudelman","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0300","unstructured":"Richard H.P. Porte, Georg Jaeschke, Will Spooren (2015) Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115855","article-title":"Novel substituted 4-(Arylethynyl)-Pyrrolo[2,3-d]pyrimidines negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) Treat depressive disorder in mice","volume":"261","author":"Du","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2021.117785","article-title":"Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers","volume":"230","author":"Streffer","year":"2021","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0315","unstructured":"Sosei Heptares (2020) Sosei Heptares and Aditum Bio create new company - Tempero Bio - to advance the clinical development of mGlu5 NAM program in neurological diseases."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0320","unstructured":"Tempero bio (2023) neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLA\u2019s position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the expansion of its portfolio into wider neuropsychiatric indications."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0325","unstructured":"John Wagner (2025) Tempero Bio Secures $70 Million Series B Financing to Advance TMP-301 into Phase 2 Trials for Substance Use Disorders."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0335","unstructured":"Stalicla (2024) STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant)."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0340","unstructured":"STALICLA (2024) STALICLA starts U.S. Phase 3 DDI study of STP7 (Mavoglurant) for cocaine use disorder."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0345","unstructured":"STALICLA (2023) STALICLA and Firefly Neuroscience partner to develop Electroencephalogram (EEG) as Biomarker for Subgroups of Patients with ASD."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0350","unstructured":"Nuala Moran (2024) Stalicla\u2019s series B adds $17.4M for trials in substance abuse disorders, ASD."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0355","unstructured":"NIH (2023) Phase1, STP7 Cocaine Drug-Drug Interaction Stud."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0360","unstructured":"James Waldron (2025) Tempero calls time on alcohol use disorder while mulling options, according to partner."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0365","doi-asserted-by":"crossref","unstructured":"Baltazar Gomez-Mancilla, Kenneth M. D\u00fcrsteler, Marc Vogel (2025) Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial. 10.1126\/scitranslmed.adi4505.","DOI":"10.1126\/scitranslmed.adi4505"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0370","unstructured":"Allosteric modulators for human health (2009) Development of ADX10059 Ended for Long-term Use."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0375","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.parkreldis.2014.05.003","article-title":"Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias","volume":"20","author":"Rascol","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0380","unstructured":"PR Newswire (2018) First Subject Dosed in Phase I Study of HTL0014242, a Selective mGlu5 Negative Allosteric Modulator in Development to Treat Psychiatric and Neurological Disorders."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0385","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3390\/molecules16032097","article-title":"Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders","volume":"16","author":"Cleva","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0390","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17070885","article-title":"Advances in liposomal drug delivery: multidirectional perspectives on overcoming biological barriers","volume":"17","author":"Sobol","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0395","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw002","article-title":"Negative allosteric modulators of metabotropic glutamate receptors subtype 5 in addiction: a therapeutic window","volume":"19","author":"Mihov","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0400","doi-asserted-by":"crossref","DOI":"10.3390\/jox15060175","article-title":"Insights into hepatic, neuronal, and hERG channel safety of plant-derived active compounds","volume":"15","author":"Kasemnitichok","year":"2025","journal-title":"J. Xenobiot."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0405","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1021\/cn2000266","article-title":"Recent advances in the design and development of novel negative allosteric modulators of mGlu 5","volume":"2","author":"Emmitte","year":"2011","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105761","article-title":"Novel rapid-acting glutamatergic modulators: targeting the synaptic plasticity in depression","volume":"171","author":"Wang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0420","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1124\/mol.114.097220","article-title":"Molecular insights into metabotropic glutamate receptor allosteric modulations","volume":"88","author":"Gregory","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0425","unstructured":"Jackson A. Kos, Monica Langiu, Shane D. Hellyer (2024) harmacology, Signaling and Therapeutic Potential of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0430","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.neuroimage.2019.02.051","article-title":"Inhibiting mGluR5 activity by AFQ056\/Mavoglurant rescues circuit-specific functional connectivity in Fmr1 knockout mice","volume":"191","author":"Zerbi","year":"2019","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117030","article-title":"Pharmacological characterisation of allosteric modulators at human mGlu5","volume":"239","author":"Razzak","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0440","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1021\/acschemneuro.7b00167","article-title":"Role of mGlu5 receptors and inhibitory neurotransmission in M1 dependent muscarinic LTD in the prefrontal cortex: implications in schizophrenia","volume":"8","author":"Ghoshal","year":"2017","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0445","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15112599","article-title":"Non-invasive drug delivery across the blood\u2013brain barrier: a prospective analysis","volume":"15","author":"Niazi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0450","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16121611","article-title":"Drug delivery across the blood\u2013brain barrier: a new strategy for the treatment of neurological diseases","volume":"16","author":"Jiao","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuroscience.2026.08.002_b0060","unstructured":"Berry-Kravis E, Des Portes V, Hagerman R, et al F R A G I L E X S Y N D R O M E Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0235","unstructured":"Butkiewicz M, Rodriguez AL, Rainey SE, et al Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding HHS Public Access. 10.1021\/acschemneur-o.8b00227."},{"key":"10.1016\/j.neuroscience.2026.08.002_b0330","unstructured":"Negida A, Ghaith HS, Yousry Fala S, et al Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson\u2019s disease: a meta-analysis. 10.1007\/s10072-021-05319-7\/Published."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226005312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226005312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:25:38Z","timestamp":1789129538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226005312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":89,"alternative-id":["S0306452226005312"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.08.002","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An updated patent review of mGlu5 negative allosteric modulators (2018 \u2212 present)","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}